In this exclusive interview Tobias Noeske, Associate Principal Scientist from AstraZeneca, speaks to Andrea Charles from Pharma IQ.   Noeske describes how AstraZeneca are reducing compound attrition rates arising from drug-induced liver injury (DILI).  DILI is a major cause for attrition in clinical trials, which can cost hundreds of million of dollars in the late stages of drug development.

Noeske explains how in silico models can identify and mitigate compound-related safety issues during early drug discovery. Using the emerging transporter BSEP as a case study, he explains how combining in vitro screening within silico QSAR models saves time, money and improves thein vitro – in vivo correlation in downstream toxicology studies. With the ITC recommending BSEP to join the list of transporter studies required for regulatory approval, AstraZeneca already have an strategy to deploy and refine.

[inlinead]